After the slimming treatment Merck Sharp & Dohme resumes investing in Italy. On the plate there are 200 million euros that the American pharmaceutical industry plans to allocate over the next five years to the expansion of the research center in Pomezia. where he has already staked 180 million in the period 2002-2006. with the firm will to make Italy one of the strategic bases in Europe and win other challenges on the most advanced frontier of pharmaceuticals. A choice defined as courageous by the exponents of the company themselves, due to the strong regulation that exists today in the country, pressed by the pressing need to control costs. On the other hand, the effort to create a fund for innovative drugs is appreciated, which is one of the reasons that prompted Merck to invest again in our country after the heavy restructuring of the last two years with which it was desired to avoid maximizing sales in a short-term commercial perspective. A repositioning that perhaps also comes to the detriment of the logistics activity a little, but rewards the quality of the research in Pomezia.
Logistics and Management of 16/07/2008 JUNE/JULY 2008 p. 27 balls
